Microfluidic Components Market Report: Expected to exceed 2.18 billion yuan in 2031

According to the microfluidic components market report released by YH Research, this report provides the situation, definition, classification, application, and industrial chain structure of the microfluidic components market. It also discusses development policies and plans, manufacturing processes, and cost structures, and analyzes the current development status and future market trends of the microfluidic components market. It also analyzes the main production areas, main consumption areas, and main manufacturers of the microfluidic component market from the perspectives of production and consumption.

YH Research data shows that the global microfluidic component market size will reach 1.56 billion yuan in 2024 and is expected to exceed 2.18 billion yuan in 2031, with a compound annual growth rate (CAGR) of 4.9% from 2025 to 2031. Due to the impact of the U.S. “2025 Biosecurity Act” implementing “supply chain traceability reviews” for precision valve bodies used in microfluidic chips (effective in 2026) and the EU “In Vitro Diagnostic Medical Devices Regulation” (IVDR) upgrading requirements for component biocompatibility certification (mandatory enforcement in 2027), the global market exhibits dual characteristics of “accelerated technological self-reliance” and “deepening precision medicine applications.” This report is based on historical data from 2020 to 2024, the revision dynamics of the ISO 21649:2024 microfluidic component standard, and the production capacity layout of leading companies. It provides an in-depth analysis of the technological iteration path, regional market potential, and the commercialization process of emerging application scenarios.

I. Technical Characteristics and Industrial Value
Microfluidic components achieve precise fluid control through micron-level channels, with core parameters including:

Fluid control precision:
Flow rate resolution: High-end micro-pumps (such as IDEX's M6 series) can achieve flow rate control at the 0.1 μL/min level (ISO 21649 requirement: ≤±5%);


Pressure stability: Bürkert's micro-pressure regulators maintain ±0.1% fluctuation within the 0-10 bar range (meeting POCT device requirements).


Application scenario adaptability:
Medical diagnostics: Supports micro-upgrade reagent dispensing for PCR amplifiers (e.g., Tecan's Fluent automated workstation);


Drug development: Enables microfluidic chip integration for single-cell screening (e.g., Dolomite's Nadia Innovate platform).

Microfluidic components


II. Market Drivers and Growth Logic


Explosion in Precision Medicine Demand
Point-of-Care Testing (POCT): Demand for COVID-19 antigen test kits is driving microfluidic valve body procurement volumes (global growth of 38% by 2024), such as Fluigent's Flow EZ pressure controller, which holds over 40% market share in molecular diagnostic devices;


Cell Therapy: CAR-T therapy requires microfluidic chips for single-cell separation (e.g., Chemyx's Fusion 100 syringe pump has a penetration rate of 65% in cell preparation processes).


Policy and Standards-Driven
FDA 510(k) Certification: Starting in 2025, new requirements for the biocompatibility of microfluidic component materials (ISO 10993-5 standard) will be introduced, forcing companies to upgrade their processes;


China's 14th Five-Year Plan for the Bioeconomy: Requires domestic production rates for microfluidic technology to exceed 80% by 2025, driving technological breakthroughs by domestic companies (e.g., Shenzhen Kento's micro-diaphragm pump achieving over 10 million cycle lifetimes).


III. Market Challenges and Risk Analysis


Supply Chain Vulnerability
Reliance on Precision Processing: Over 90% of piezoelectric ceramics (PZT) used in microfluidic valve bodies are imported (affected by Japanese export controls, prices rose by 28% year-on-year in 2024);


Regional Concentration of Production Capacity: The top five global manufacturers (SMC, IDEX, etc.) account for over 60% of production capacity, posing significant risks of regional supply disruptions (e.g., the 2023 Southeast Asian chip shortage caused Tecan's delivery cycle to extend by four months).


Technological Upgrade Pressure
Integration改造 costs: Developing multi-channel microfluidic modules (e.g., Elveflow's OB1 MK3+ pressure controller) requires an additional 15%-25% of equipment costs;


Interdisciplinary technical barriers: The integration of microfluidics with microelectronics and biosensing requires breakthroughs in surface modification technology (only a few companies globally, such as SMC and Bürkert, master hydrophilic/hydrophobic coating processes).


IV. Downstream Demand Trends and Application Expansion


High-End Development in Traditional Fields
In Vitro Diagnostics: EU regulations in 2024 require digital PCR devices to have microfluidic modules with anti-cross-contamination design (e.g., Bartels Mikrotechnik's qPCR chip);


Pharmaceutical R&D: Microfluidic organ-on-a-chip systems must simulate blood flow shear stress (e.g., Harvard Apparatus' Pump 11 Elite supports dynamic adjustment from 0.01 to 100 dyn/cm²).


Emerging Field Explosion
Space Biology: NASA's microgravity experiment module scheduled for launch in 2026 will carry a microfluidic cell culture system (e.g., Norgren's micro electromagnetic valve);


Agricultural Breeding: High-throughput plant phenotyping analysis requires microfluidic chips to achieve single-seed droplet manipulation (e.g., New Era Instruments' NE-9000 injection pump).


V. Competitive Landscape and Regional Differentiation
The global market presents a “Western technological monopoly and rising Asia-Pacific production capacity” landscape:

Western manufacturers: SMC and IDEX dominate the high-end market (price > 3,000 RMB per unit) and maintain their advantage through patent barriers (e.g., IDEX's microvalve sealing structure patent valid until 2029);


Asia-Pacific manufacturers: Shenzhen Hengyongda and Baoding Langge leverage cost advantages to hold over 50% market share in the mid-to-low-end market (price < RMB 500 per unit), but precision processing consistency (CV value < 3%) still lags behind international standards.